I would like to tell you about the experience we are having in creating a new institute for biomedical research in London. The idea of setting up this institute developed while we were at the Wellcome Research Laboratories where there was a great environment that combined basic research and research for drug discovery in a very efficient way. I started to wonder whether such an environment could be created in a university set-up, away from the commercial pressures which were already threatening the functioning of Wellcome. Furthermore, I thought that in a climate of reduced government support for academic research the university could generate its own funding by exploiting the intellectual property that it creates in a more effective manner.
The idea of the Cruciform Project was to create a large, multidisciplinary team, securely funded for a reasonable period, working together in an integrated way. Rather than having isolated groups working on different aspects of the same problem we would try to tackle problems related to human pathophysiology in a coordinated way. Part of the idea was also to bring together in the academic environment two previously contradictory realities, namely fundamental research and applied research orientated towards application.
What has happened in the past, and is still happening, is that research in the universities is carried out independently of practical application. That leads to a large gap between the generation of knowledge and its utilization, so we wanted to work at the interface of academic and industrial Director, The Wolfson Institute for Biomedical Research research to effect a more efficient transfer of intellectual property and of understanding.
The other decision we made was to work on areas related to chronic degenerative diseases. The molecular and biochemical mechanisms of these different conditions can be tackled independently of the final therapeutic objective and will ultimately lead to the discovery of new drugs. Apart from cellular and molecular biology, pharmacology and biochemistry we wanted to bring the strength of medicinal chemistry into biological research. The primary objective was to make chemicals to probe biochemical or molecular mechanisms. This, besides helping the elucidation of these mechanisms, may be the beginning of the creation of prototype molecules for the discovery of new medicines.
In addition, an integral part of the Institute was to be the development of clinical pharmacology and clinical research. That would bring us directly in contact with medical practice and with the National Health Service and thus allow translational research into human conditions. So where are we going? In January 2000 we will have 6000 m2 of space in the old University College Hospital building that was vacated as part of the reorganization of the National Health Service. The building, whose shape gives rise to the name Cruciform, was empty for several years before the University bought it from the NHS. One-third of it will be dedicated to teaching the basic medical sciences for students of the integrated medical schools around UCL and the four upper floors will form the Institute. We have changed the name to The Wolfson Institute for Biomedical Research at the Cruciform Building in response to a generous gift of £10 million from the Wolfson Foundation.
The building, which is a very expensive renovation project costing around £50 million, is to be funded by a Private Finance Initiative. How are we going to finance the research? It is intended that this will be achieved by a 50% contribution from academic sources of funding and 50% from industrial sources. At the moment we have managed to raise about £22 million for research, more than 50% of which comes from industrial sources, but we are increasingly being funded by different bodies such as The Wellcome Trust, The Medical Research Council and The British Heart Foundation.
All the intellectual property that is generated in the Institute will be deposited in a holding company-UCL Cruciform Ltd. The owners of this company in the long term will be UCL and a Trust that we have created to support basic research at the Institute. Any piece of intellectual property generated which is amenable to industrial development will be managed by a subsidiary company in order to attract extra money for the development of an idea or a project with a specific objective. So far, we have created four such companies. The structure of the ownership of these companies ensures that a sizeable amount of the money generated will be returned to the Trust. In this way we will achieve the Institute's dual objectives, namely the operation at the interface between academic and applied research and the creation of an alternative source of funding for fundamental research.
